KONEXBiotech & Pharma354390

BASKHANBIOPharma

₩3,500 0.00%2026-11-18 close
Market Cap
₩24.6B
Turnover
₩3,500
Volume
1 shares
Shares out.
7M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Profit Growth Versus Share Price Weakness

BASKHANBIOPharma's operating profit reached KRW 2,895 million in 2025, while its share price has fallen from KRW 5,900 in early September 2025 to KRW 3,210.

  1. 1

    The 40th-term separate financial statements for 2025, showing revenue of KRW 33,520 million, operating profit of KRW 2,895 million and net income of KRW 4,766 million, were approved at the annual shareholders' meeting on March 26, 2026.

  2. 2

    According to fnguide aggregates, the operating margin rose from 4.31% in 2024 to 8.64% in 2025, and revenue increased from KRW 28.9 billion to KRW 33.5 billion over the same period.

  3. 3

    The share price closed at KRW 5,900 on September 1, 2025, moved to KRW 4,800 on March 30, 2026, and stood at KRW 3,210 on November 11, 2026, down 8.02% from the prior session.

  4. 4

    The stake held by the de facto controlling shareholder and related parties stood at 22.23% as of March 30, 2026, after a reduction of 25,946 shares tied to the expiry of a stock option exercise period and an executive's departure.

  5. 5

    At year-end 2025, total equity was KRW 36,140 million and total liabilities were KRW 4,840 million, with a debt-to-equity ratio of 13.39%, indicating a comparatively light debt burden.

02

Business structure

BASKHANBIOPharma was founded in 1986 as Hanbul Pharmaceutical and was acquired by a Legochem group affiliate in December 2015, after which it changed its name in 2020 following a merger with Medizone. The company operates a production base in Anseong, Gyeonggi Province, where its second plant was completed in 2016.

Its core business is prescription drugs, and fnguide describes its specialty as drugs and medical devices used before, during and after surgery. The company's website lists medicines, medical devices, health functional foods and cosmetics as business areas, with medicines as the central pillar.

Health functional foods and cosmetics appear mainly through trade fair participation, suggesting a limited contribution to revenue. Within the Korean pharmaceutical sector, revenue of KRW 33,520 million is small compared with large listed drugmakers such as Hanmi Pharm and Yuhan.

The company received government approval for a business restructuring support program in 2022 and completed a smart factory project in 2020. According to fnguide, R&D expenses declined from KRW 500 million in 2022 to KRW 300 million in 2023 and KRW 100 million in 2024.

03

Recent trends

Based on the 40th-term separate financial statements for January 1 to December 31, 2025 disclosed via DART, revenue was KRW 33,520 million, operating profit was KRW 2,895 million and net income was KRW 4,766 million, with net income exceeding operating profit.

The statements were approved at the shareholders' meeting on March 26, 2026, and the separate-basis audit opinion was unqualified. According to fnguide aggregates, annual revenue was KRW 30.4 billion in 2023, KRW 28.9 billion in 2024 and KRW 33.5 billion in 2025, rebounding in 2025.

Operating profit over the same aggregates was KRW 1.2 billion in 2023, KRW 1.2 billion in 2024 and KRW 2.9 billion in 2025, lifting the operating margin from 4.31% to 8.64%.

Net income of KRW 2.8 billion in 2023, KRW 2.8 billion in 2024 and KRW 4.8 billion in 2025 exceeded operating profit, and 2024 other income of KRW 1.4 billion included KRW 1.0 billion from gains on asset disposal. The 2025 composition of non-operating items is set out by item in the business report notes.

The share price closed at KRW 5,900 on September 1, 2025, recorded KRW 4,800 on March 30, 2026, and stood at KRW 3,210 on November 11, 2026. On September 1, 2025, outside director Min Cheon-gi reported an open-market purchase of 13,000 shares at KRW 5,428 per share, raising his stake to 0.19%. The 52-week high and low shown on the fnguide quote page are KRW 5,900 and KRW 3,635.

04

Outlook

The company's direction will depend largely on whether its operating margin holds near the 2025 level. The 8.64% margin in 2025 was higher than the 4.31% recorded in 2024, but a single year is too short a period to establish a trend.

The decline in R&D spending since 2022 is a factual constraint on the pace of new product and pipeline development. Because revenue is concentrated in prescription drugs, reimbursement price adjustments and generic competition feed directly into earnings.

The stake held by the de facto controlling shareholder and related parties was 22.23% as of March 30, 2026, and the free float ratio stood at 69.79% according to fnguide. The reduction in that stake is linked to the expiry of a stock option exercise period and an executive's departure.

No dividend record has been identified, so shareholder return policy is limited to what current disclosures show. As a KONEX-listed company, its trading liquidity and frequency of information disclosure are lower than those of large drugmakers on KOSPI or KOSDAQ.

Key indicators that will show the business trajectory are the operating margin, the R&D spending trend and the product mix of prescription drugs.

05

Bull factors

Improving profitability

According to fnguide aggregates, the operating margin rose from 4.31% in 2024 to 8.64% in 2025, with operating profit of KRW 2,895 million. Profit growth outpaced revenue growth as revenue rose to about KRW 33.5 billion over the same period.

The unqualified audit opinion on the 2025 separate financial statements also supports the reliability of the company's reported figures.

Balance sheet capacity

Total equity at year-end 2025 was KRW 36,140 million, against total liabilities of KRW 4,840 million. fnguide shows a debt-to-equity ratio of 13.39% and a reserve ratio of 105.98%, both indicating an equity-based capital structure.

With total assets of KRW 40,980 million largely funded by equity, the company's exposure to borrowing conditions is comparatively limited.

Insider open-market purchase

On September 1, 2025, outside director Min Cheon-gi reported an open-market purchase of 13,000 shares at KRW 5,428 per share, bringing his holding to 0.19%. The filing records the purchase and price but does not state the reason for it.

The share price on that date was around KRW 5,900, so the reported purchase price differed from the market level at the time.

06

Bear factors

Share price decline and shifting shareholder structure

The share price fell from KRW 5,900 on September 1, 2025 to KRW 4,800 on March 30, 2026, and reached KRW 3,210 on November 11, 2026, down 8.02% in the latest session.

The stake held by the de facto controlling shareholder and related parties was reported at 22.23% as of March 30, 2026, with 25,946 shares reduced during the reporting period. As a KONEX-listed stock, its price movements and trading concentration can differ from those of larger listed companies.

Shrinking R&D investment

According to fnguide aggregates, R&D expenses fell from KRW 500 million in 2022 to KRW 300 million in 2023 and KRW 100 million in 2024. With investment in new products and indication expansion declining, the visibility of medium-term growth drivers is limited.

The company established an in-house research institute in 2022, but R&D spending has remained small relative to revenue.

Limited scale and concentrated portfolio

Revenue of about KRW 33.5 billion is small compared with large listed drugmakers such as Hanmi Pharm and Yuhan. Because the portfolio is concentrated in prescription drugs for surgery and pain, price adjustments or supply disruptions in a single product group can have a large effect on results.

The company's notice history includes a drug recall announcement dated December 7, 2021, which keeps quality management a continuing consideration.

07

Risk factors

Macro and policy

A business centered on prescription drugs is directly affected by changes in drug pricing rules and reimbursement listing policy. Intensifying generic competition could weigh on both prices and market share of key products.

Government support for the pharmaceutical industry has so far been applied to individual companies, as seen in the 2022 business restructuring approval.

Operations and quality

A drug recall announcement dated December 7, 2021 underscores the importance of production and quality control systems. Because operations are concentrated at the Anseong production base, any suspension of plant operations could cause a revenue gap.

Although the smart factory upgrade was completed in 2020, capital expenditure and staffing demands remain ongoing.

Governance and liquidity

The stake held by the de facto controlling shareholder and related parties was 22.23% as of March 30, 2026, and changes in this structure are being disclosed. According to fnguide, the free float ratio is 69.79%, and the tradable share base affects how the share price moves.

The KONEX market has smaller information flow and trading volume than KOSPI or KOSDAQ, which can make the share price more volatile.

08

Overall view

BASKHANBIOPharma recorded revenue of KRW 33,520 million and operating profit of KRW 2,895 million on a 2025 separate basis, and according to fnguide aggregates its operating margin rose from 4.31% in 2024 to 8.64% in 2025.

Its capital structure is equity-based, with total equity of KRW 36,140 million and a debt-to-equity ratio of 13.39%.

On the other hand, the share price moved from KRW 5,900 on September 1, 2025 to KRW 3,210 on November 11, 2026, and the stake held by the de facto controlling shareholder and related parties was reported at 22.23% after a recent reduction in shares.

R&D spending has trended down since 2022, and revenue remains small compared with large listed drugmakers. An insider's open-market purchase is confirmed by filing, but the reason is not stated in the filing.

Margin improvement and balance sheet capacity form the bullish side, while the share price decline, shrinking R&D and portfolio concentration form the bearish side. This report is provided for information only and does not express a view on the direction of the share price.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 9 more articles and sources
  1. news.nate.com
  2. m.news.nate.com
  3. digitaltoday.co.kr
  4. comp.fnguide.com
  5. comp.fnguide.com
  6. kind.krx.co.kr
  7. kind.krx.co.kr
  8. baskhanbio.com
  9. baskhanbio.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis